Skip to search formSkip to main contentSkip to account menu

lurtotecan liposome

Known as: liposomal lurtotecan, liposome, lurtotecan 
A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

NX 211OSI 211
lurtotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… 
2005
2005
Phase I study of OSI-211 (liposomal lurtotecan) in combination with liposomal doxorubicin (LD) every 3 weeks in patients (pts) with advanced solid tumors; final analysis suggests benefit in…
2074 Background: OSI-211 is a topoisomerase (topo) I inhibitor in liposomal formulation. In vivo efficacy of the liposomal… 
2005
2005
Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC)
5017 Background: OSI-211 is a liposomal formulation of lurtotecan, a topoisomerase-I inhibitor. In a previous randomised dose… 
2005
2005
P-789 Phase II study of OSI-211 (liposomal lurtotecan) in recurrentsmall-cell lung cancer (SCLC)
Highly Cited
2004
Highly Cited
2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
2004
2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
2004
2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal… 
2003
2003
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
2001
2001
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice
  • John P DesjardinsElizabeth A Abbott Frank C Richardson
  • Anti-Cancer Drugs
  • 2001
  • Corpus ID: 40347972
Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. Lurtotecan… 
1999
1999
Clinical pharmacokinetics of liposomal lurtotecan (NX211) in whole blood, plasma and urine.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)